Objective:To investigate the impact of endocrine therapy(ET)on the prognosis of breast cancer patients with low estrogen re-ceptor(ER)expression and to identify the associated independent prognostic factors.Methods:We retrospectively analyzed the clinicopath-ological data of 387 female patients with breast cancer with low ER expression and at stage Ⅰ-Ⅲ TNM who were treated surgically at Xinji-ang Medical University Affiliated Tumor Hospital between January 2014 and May 2020.The patients were stratified into ET and non-ET groups based on whether they received ET administration.Propensity score matching(PSM)was used to balance intergroup differences,and survival analysis along with Cox proportional hazards models were applied to assess prognosis and the associated independent influencing factors.Results:Among the 387 patients,214(55.3%)received ET and 173(44.7%)did not.Baseline data indicated that the non-ET group exhibited higher proportions of ethnic minorities and patients with regional lymph node involvement,advanced TNM stage,and no radio-therapy administration.After PSM,baseline characteristics showed no significant differences between the ET(n=132)and non-ET groups(n=132).Pre-PSM survival analysis revealed 5-year overall survival(OS)rates of 93.4%and 72.8%and 5-year disease-free survival(DFS)rates of 74.1%and 60.9%for the ET and non-ET groups,respectively;both rates showed statistically significant differences between the groups(P<0.05).Post-PSM,the 5-year OS rates significantly differed between the ET and non-ET groups(91.6%and 80.1%,respectively;P<0.05),whereas no significant difference in 5-year DFS rates were observed(71.1%[ET group]vs.68.1%[non-ET group],P>0.05).Multivariate ana-lysis identified the following independent prognostic factors:for OS,ET administration,CK5/6 status,tumor size T3,lymph node status N2/N3,and radiotherapy administration(all P<0.05).For DFS,the independent factors included CK5/6 status,tumor size T3,lymph node status N2/N3,radiotherapy administration,and targeted therapy(all P<0.05).Conclusions:Endocrine therapy significantly improved the 5-year OS in breast cancer patients with low ER expression.CK5/6 positivity,large tumor size(T3),and regional lymph node involvement(N2/N3)were independent risk factors for both 5-year OS and DFS.Adjuvant radiotherapy and trastuzumab-based therapy significantly im-proved prognosis.

Objective:To investigate the impact of endocrine therapy(ET)on the prognosis of breast cancer patients with low estrogen re-ceptor(ER)expression and to identify the associated independent prognostic factors.Methods:We retrospectively analyzed the clinicopath-ological data of 387 female patients with breast cancer with low ER expression and at stage Ⅰ-Ⅲ TNM who were treated surgically at Xinji-ang Medical University Affiliated Tumor Hospital between January 2014 and May 2020.The patients were stratified into ET and non-ET groups based on whether they received ET administration.Propensity score matching(PSM)was used to balance intergroup differences,and survival analysis along with Cox proportional hazards models were applied to assess prognosis and the associated independent influencing factors.Results:Among the 387 patients,214(55.3%)received ET and 173(44.7%)did not.Baseline data indicated that the non-ET group exhibited higher proportions of ethnic minorities and patients with regional lymph node involvement,advanced TNM stage,and no radio-therapy administration.After PSM,baseline characteristics showed no significant differences between the ET(n=132)and non-ET groups(n=132).Pre-PSM survival analysis revealed 5-year overall survival(OS)rates of 93.4%and 72.8%and 5-year disease-free survival(DFS)rates of 74.1%and 60.9%for the ET and non-ET groups,respectively;both rates showed statistically significant differences between the groups(P<0.05).Post-PSM,the 5-year OS rates significantly differed between the ET and non-ET groups(91.6%and 80.1%,respectively;P<0.05),whereas no significant difference in 5-year DFS rates were observed(71.1%[ET group]vs.68.1%[non-ET group],P>0.05).Multivariate ana-lysis identified the following independent prognostic factors:for OS,ET administration,CK5/6 status,tumor size T3,lymph node status N2/N3,and radiotherapy administration(all P<0.05).For DFS,the independent factors included CK5/6 status,tumor size T3,lymph node status N2/N3,radiotherapy administration,and targeted therapy(all P<0.05).Conclusions:Endocrine therapy significantly improved the 5-year OS in breast cancer patients with low ER expression.CK5/6 positivity,large tumor size(T3),and regional lymph node involvement(N2/N3)were independent risk factors for both 5-year OS and DFS.Adjuvant radiotherapy and trastuzumab-based therapy significantly im-proved prognosis.

Objective:To compare the complications, degree of satisfaction and quality of life among breast cancer patients treated with different reconstruction methods after postoperative radiotherapy, aiming to explore the optimal combination of reconstruction and radiotherapy.Methods:105 breast cancer patients treated with postoperative radiotherapy after reconstruction surgery in Tumor Hospital from 2014 to 2019 were enrolled. According to the type of reconstruction, all patients were divided into group A (autologous reconstruction group, n=54) and group B (implant reconstruction group, n=51). Patients in group B were further divided into group B1(one-stage reconstruction group, n=30) and group B2(two-stage reconstruction group, n=21) according to the timing of reconstruction. The incidence of complications and BREAST-Q score were statistically compared between groups A and B, groups B1 and B2, respectively. The influencing factors of BREAST-Q score were identified by multiple linear regression analysis. Results:The incidence of long-term complications and the total incidence of complications in group A were significantly lower than those in group B (1.9% vs. 37.3%, P<0.001 and 9.3% vs.43.1%, P<0.001), and the scores of psychosocial well-being and degree of satisfaction with breasts in group A were significantly higher than those in group B (71(15) vs. 66(22), P=0.027 and 53(8) vs. 53(8), P=0.032)). There was no significant difference in the incidence of complications and BREAST-Q scores between groups B1 and B2(both P>0.05). Breast volume and complications were the predictors of BREAST-Q score (both P<0.001). Conclusions:Radiotherapy after autologous reconstruction of breast cancer yields fewer complications and better BREAST-Q score than the implantation reconstruction. The incidence of postoperative radiotherapy complications and BREAST-Q scores are equivalent between one-stage and two-stage reconstruction. The BREAST-Q score is lower in patients with large breasts or complications.